Immunology for
a Better Future

Learn More

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Advancing Therapeutic
Solutions

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

Focused on Improving
Lives

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Key Highlights

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA, Fla., Sept. 27, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, Chief...